At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- TSPO PET scan (11C-PBR28) (radiation)
- How long the study runs
- Study runs about 26 months (dates as stated)
- About the drug or intervention
- TSPO PET scan (11C-PBR28) — radiation: PET scan
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 25 Years to 75 Years
- Who
- All
- Number of participants
- 6
- Started
- 2023-02-01
- Last checked
- 2024-10
Plain English Summary
What is this study?
- • Testing a new treatment for pulmonary arterial hypertension
- • Clinical study - 6 participants
- • The aim of this study is to determine whether there is an increase in the TSPO PET signal (measured with the radioligand \[11C\]PBR28) in the lungs of patients living with PAH relative to age matched controls
Who can take part?
- • Ages 25 Years to 75 Years
- • Diagnosed with pulmonary arterial hypertension
Where?
- • London - Imperial Clinical Research Facility
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The aim of this study is to determine whether there is an increase in the TSPO PET signal (measured with the radioligand \[11C\]PBR28) in the lungs of patients living with PAH relative to age matched controls. If so, TSPO PET may be a useful technique to non-invasively monitor response to therapy. To do this, we will perform 2 \[11C\]PBR28 PET scans. The first will quantify the total \[11C\]PBR28 PET signal. This signal is a combination of the specific signal (VS) and the nonspecific signal (VND). The second scan will be performed following dosing with an unlabelled TSPO ligand. By directly measuring the total \[11C\]PBR28 signal (scan 1) and the nonspecific \[11C\]PBR28 signal (scan 2) we can therefore calculate the specific \[11C\]PBR28 signal, and hence the amount of TSPO in the lung.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 25 Years - 75 Years
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Able to provide written agreement to take part prior to any study mandated procedures.
- ✓Able to lie comfortably on back for up to 90 minutes at a time.
- ✓Male participants who are fertile are eligible to participate if they are willing to comply with the contraceptive...
Who cannot take part
- ✗Unable to provide agreement to take part and/or are non-fluent speakers of the English language
- ✗TT Genotype at the rs6971 locus
- ✗Clinically-significant kidney disease (confirmed by creatinine clearance \<30 ml/min per 1.73m2)
- ✗Clinically-significant liver disease (confirmed by serum transaminases \>2 times than upper normal limit)
- ✗Anaemia confirmed by haemoglobin concentration \<10 g/dl
See the full criteria
Where Is This Study? (1 UK site)
Imperial Clinical Research Facility
London NW3 2LE, United Kingdom